Aurinia to Participate in Upcoming Investor Healthcare Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announces participation in upcoming investor conferences in March 2024, including TD Cowen’s 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. Management will engage in one-on-one meetings, fireside chats, and Q&A sessions to discuss the company's progress and future plans.
02/27/2024 - 08:30 AM
ROCKVILLE, Md. & EDMONTON, Alberta --(BUSINESS WIRE)--
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that management will be participating in the following upcoming investor conferences during the month of March:
TD Cowen’s 44th Annual Health Care Conference taking place March 4 - 6, 2024, at the Marriott Copley Place in Boston, MA. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, March 5, from 1:30-2:00 PM Eastern Time. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found here .
Leerink Partners Global Biopharma Conference taking place March 11-13, 2024, at the Fontainebleau Miami Beach. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, March 12, from 8:40 – 9:10 AM Eastern Time. The session will not include a webcast.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta , its U.S. commercial office is in Rockville, Maryland . The Company focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227383351/en/
Media and Investor Inquiries:
Andrea Christopher
Corporate Communications and Investor Relations, Aurinia
achristopher@auriniapharma.com
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals is participating in TD Cowen’s 44th Annual Health Care Conference from March 4 - 6, 2024, and Leerink Partners Global Biopharma Conference from March 11-13, 2024.
Aurinia management will engage in one-on-one meetings with investors, participate in fireside chats, and host Q&A sessions to discuss the company's progress and future plans.
Investors can watch the live webcast of the session on March 5 on the Investor section of Aurinia’s website.
No, the session at Leerink Partners Global Biopharma Conference on March 12 will not include a webcast.
Aurinia Pharmaceuticals Inc
AUPH Rankings
#2796 Ranked by Stock Gains
AUPH Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Canada
City
Victoria
About AUPH
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.